Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies

BACKGROUND: Low-risk limits recommended for alcohol consumption vary substantially across different national guidelines. To define thresholds associated with lowest risk for all-cause mortality and cardiovascular disease, we studied individual-participant data from 599 912 current drinkers without previous cardiovascular disease.

METHODS: We did a combined analysis of individual-participant data from three large-scale data sources in 19 high-income countries (the Emerging Risk Factors Collaboration, EPIC-CVD, and the UK Biobank). We characterised dose-response associations and calculated hazard ratios (HRs) per 100 g per week of alcohol (12.5 units per week) across 83 prospective studies, adjusting at least for study or centre, age, sex, smoking, and diabetes. To be eligible for the analysis, participants had to have information recorded about their alcohol consumption amount and status (ie, non-drinker vs current drinker), plus age, sex, history of diabetes and smoking status, at least 1 year of follow-up after baseline, and no baseline history of cardiovascular disease. The main analyses focused on current drinkers, whose baseline alcohol consumption was categorised into eight predefined groups according to the amount in grams consumed per week. We assessed alcohol consumption in relation to all-cause mortality, total cardiovascular disease, and several cardiovascular disease subtypes. We corrected HRs for estimated long-term variability in alcohol consumption using 152 640 serial alcohol assessments obtained some years apart (median interval 5.6 years [5th-95th percentile 1.04-13.5]) from 71 011 participants from 37 studies.

FINDINGS: In the 599 912 current drinkers included in the analysis, we recorded 40 310 deaths and 39 018 incident cardiovascular disease events during 5.4 million person-years of follow-up. For all-cause mortality, we recorded a positive and curvilinear association with the level of alcohol consumption, with the minimum mortality risk around or below 100 g per week. Alcohol consumption was roughly linearly associated with a higher risk of stroke (HR per 100 g per week higher consumption 1.14, 95% CI, 1.10-1.17), coronary disease excluding myocardial infarction (1.06, 1.00-1.11), heart failure (1.09, 1.03-1.15), fatal hypertensive disease (1.24, 1.15-1.33); and fatal aortic aneurysm (1.15, 1.03-1.28). By contrast, increased alcohol consumption was log-linearly associated with a lower risk of myocardial infarction (HR 0.94, 0.91-0.97). In comparison to those who reported drinking >0-100-200-350 g per week had lower life expectancy at age 40 years of approximately 6 months, 1-2 years, or 4-5 years, respectively.

INTERPRETATION: In current drinkers of alcohol in high-income countries, the threshold for lowest risk of all-cause mortality was about 100 g/week. For cardiovascular disease subtypes other than myocardial infarction, there were no clear risk thresholds below which lower alcohol consumption stopped being associated with lower disease risk. These data support limits for alcohol consumption that are lower than those recommended in most current guidelines.

FUNDING: UK Medical Research Council, British Heart Foundation, National Institute for Health Research, European Union Framework 7, and European Research Council.

Additional Info

  • Authors:

    Wood,A.M.; Kaptoge,S.; Butterworth,A.S.; Willeit,P.; Warnakula,S.; Bolton,T.; Paige,E.; Paul,D.S.; Sweeting,M.; Burgess,S.; Bell,S.; Astle,W.; Stevens,D.; Koulman,A.; Selmer,R.M.; Verschuren,W.M.M.; Sato,S.; Njolstad,I.; Woodward,M.; Salomaa,V.; Nordestgaard,B.G.; Yeap,B.B.; Fletcher,A.; Melander,O.; Kuller,L.H.; Balkau,B.; Marmot,M.; Koenig,W.; Casiglia,E.; Cooper,C.; Arndt,V.; Franco,O.H.; Wennberg,P.; Gallacher,J.; de la Camara,A.G.; Volzke,H.; Dahm,C.C.; Dale,C.E.; Bergmann,M.M.; Crespo,C.J.; van der Schouw,Y.T.; Kaaks,R.; Simons,L.A.; Lagiou,P.; Schoufour,J.D.; Boer,J.M.A.; Key,T.J.; Rodriguez,B.; Moreno-Iribas,C.; Davidson,K.W.; Taylor,J.O.; Sacerdote,C.; Wallace,R.B.; Quiros,J.R.; Tumino,R.; Blazer,D.G.; Linneberg,A.; Daimon,M.; Panico,S.; Howard,B.; Skeie,G.; Strandberg,T.; Weiderpass,E.; Nietert,P.J.; Psaty,B.M.; Kromhout,D.; Salamanca-Fernandez,E.; Kiechl,S.; Krumholz,H.M.; Grioni,S.; Palli,D.; Huerta,J.M.; Price,J.; Sundstrom,J.; Arriola,L.; Arima,H.; Travis,R.C.; Panagiotakos,D.B.; Karakatsani,A.; Trichopoulou,A.; Kuhn,T.; Grobbee,D.E.; Barrett-Connor,E.; van,Schoor N.; Boeing,H.; Overvad,K.; Kauhanen,J.; Wareham,N.; Langenberg,C.; Forouhi,N.; Wennberg,M.; Despres,J.P.; Cushman,M.; Cooper,J.A.; Rodriguez,C.J.; Sakurai,M.; Shaw,J.E.; Knuiman,M.; Voortman,T.; Meisinger,C.; Tjonneland,A.; Brenner,H.; Palmieri,L.; Dallongeville,J.; Brunner,E.J.; Assmann,G.; Trevisan,M.; Gillum,R.F.; Ford,I.; Sattar,N.; Lazo,M.; Thompson,S.G.; Ferrari,P.; Leon,D.A.; Smith,G.D.; Peto,R.; Jackson,R.; Banks,E.; Di,Angelantonio E.; Danesh,J.

  • Issue: Lancet / pages 1513-1523 / volume 391
  • Published Date: 2018/4/14
  • More Information:

    For more information about this abstract, please contact
    This email address is being protected from spambots. You need JavaScript enabled to view it. at the Deutsche Weinakademie GmbH

Read 20 times

Our Partners

 
 

Contact us

We love your feedback. Get in touch with us.

  • Hot line: +32 (0)2 230 99 70
  • Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Connect with us

We're on Social Networks. Follow us.

Disclaimer

The authors have taken reasonable care in ensuring the accuracy of the information herein at the time of publication and are not responsible for any errors or omissions. Read more on our disclaimer and Privacy Policy.